<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial treatment of IDH-mutant, 1p/19q-codeleted oligodendroglioma (grade 2 and 3) in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial treatment of IDH-mutant, 1p/19q-codeleted oligodendroglioma (grade 2 and 3) in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial treatment of IDH-mutant, 1p/19q-codeleted oligodendroglioma (grade 2 and 3) in adults</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_footnotes"><p>IDH: isocitrate dehydrogenase;
	MRI: magnetic resonance imaging;
	WHO: World Health Organization;
	RT: radiation therapy;
	PCV: procarbazine, lomustine, vincristine.</p>
<p>* Modest amounts of residual grade 2 tumor after surgery, even measuring &gt;1 to 2 cm, may be reasonably observed in some cases, provided that the patient is asymptomatic from the tumor aside from well-controlled epilepsy. </p>
<p>¶ Patients who are uncomfortable with the uncertainties of observation may reasonably choose immediate postoperative therapy, even though this approach is associated with more side effects in the short term. In addition, individual risk factors (eg, age &gt;40 to 50 years, preoperative tumor volume ≥4 cm, neurologic deficits) are sometimes used to select patients for immediate further therapy after gross total resection. Practice in this area varies among experts.</p>
<p>Δ Treatment at the time of progression is individualized and may include reresection prior to administration of further therapy. Refer to UpToDate topic on treatment of oligodendroglioma for further details.</p>
	
	◊ Both PCV and temozolomide are reasonable options for adjuvant therapy along with RT in oligodendrogliomas. An ongoing randomized trial in oligodendrogliomas is comparing PCV with concurrent and adjuvant temozolomide. Refer to UpToDate topic on treatment of oligodendrogliomas for further details.</div><div id="graphicVersion">Graphic 138450 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
